🇺🇸 FDA
Patent

US 8367052

Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies

granted A61KA61K2039/505A61K31/282

Quick answer

US patent 8367052 (Methods for promoting protection and regeneration of bone marrow using CXCL9 and anti-CXCL9 antibodies) held by GENERAL REGENERATIVES, LTD. expires Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
GENERAL REGENERATIVES, LTD.
Grant date
Tue Feb 05 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 31 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K31/282, A61K31/351, A61K31/498